Allarity Therapeutics (NASDAQ:ALLR) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Allarity Therapeutics (NASDAQ:ALLR) released its quarterly earnings data on Friday. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04, FiscalAI reports.

Allarity Therapeutics Stock Performance

Shares of NASDAQ:ALLR opened at $1.37 on Friday. The company has a market capitalization of $21.80 million, a P/E ratio of -1.76 and a beta of 0.51. The company’s 50-day moving average is $1.31 and its 200 day moving average is $1.26. Allarity Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.35.

Analysts Set New Price Targets

Several research firms have commented on ALLR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Allarity Therapeutics to a “hold” rating in a report on Saturday, May 30th. Finally, Ascendiant Capital Markets raised their price objective on Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a research note on Monday, June 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Allarity Therapeutics currently has a consensus rating of “Hold” and an average price target of $10.25.

Institutional Investors Weigh In On Allarity Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of Allarity Therapeutics in the 4th quarter worth $36,000. DRW Securities LLC purchased a new stake in Allarity Therapeutics during the fourth quarter valued at about $133,000. Renaissance Technologies LLC increased its holdings in shares of Allarity Therapeutics by 274.1% in the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after buying an additional 181,426 shares during the period. Citadel Advisors LLC bought a new stake in shares of Allarity Therapeutics in the 3rd quarter valued at about $149,000. Finally, Private Advisor Group LLC bought a new position in shares of Allarity Therapeutics in the third quarter worth approximately $441,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.